Activated prothrombin complex concentrate (FEIBA®) in acquired haemophilia A: a large multicentre Italian study - the FAIR Registry

Authors: Zanon, E., Pasca, S., Santoro, C., Gamba, G., Siragusa, S. M., Rocino, A., Cantori, I., Federici, A. B., Mameli, L., Giuffrida, G., Falanga, A., Lodigiani, C., Santoro, R. C., Milan, M., Ambaglio, C., Napolitano, M., and Mazzucconi, M. G.

Published: Br.J Haematol.; 184,5:853-855. December 2019

Affiliations: Haemophilia Centre, University Hospital of Padua, Padova, Italy ; Cellular Biotechnology and Haematology Department, Umberto I University Hospital, Roma, Italy ; Haemophilia Centre, S. Matteo Hospital, Pavia, Italy ; Centre of Haemorrhagic and Thrombotic Diseases, University of Palermo, Palermo, Italy ; Haemophilia and Thrombosis Centre, S. Giovanni Bosco Hospital, Napoli, Italy ; Centre of Coagulation Diseases, Hospital of Macerata, Macerata, Italy ; Haematology and Transfusion Medicine Department, Luigi Sacco Hospital, Milano, Italy ; Center of Coagulation Diseases, SS Annunziata Hospital, Sassari, Italy ; Haematology Department, VE Ferrarotto and S. Bambino University Hospital, Catania, Italy ; Transfusion Medicine and Immune-haematology Department, Giovanni XXIII Hospital, Bergamo, Italy ; Medicine Department, Humanitas Clinical Institute, Rozzano (Milano), Italy ; Centre of Haemorrhagic and Thrombotic Diseases, Pugliese-Ciaccio Hospital, Catanzaro, Italy.

Aim: This study aimed to assess dosage, duration of treatment, as well as the effectiveness and safety of activated prothrombin complex concentrate (aPCC) in patients with AHA. Secondary objectives were the evaluation of the role of the concomitant use of antifibrinolytic agents, anamnestic response and the number of relapses, along with effectiveness of a short-term prophylactic treatment with aPCC starting after the first bleeding episode. The FAIR study is a retrospective-prospective registry that included patients with AHA treated with aPCC (FEIBA) at 12 Italian Haemophilia Centres. The study collected data from January 2003 to December 2012 for the retrospective group, and from January 2013 to December 2015 for the prospective one. Fifty-six patients were included in the registry, seven of whom had been included in a previous study (Zanon et al, 2015).